https://prtimes.jp/main/html/rd/p/000000010.000088821.html

InnoJin, Inc, Ltd. (Headquarters: Bunkyo-ku, Tokyo, Representative Director: Takenori Inomata), a venture company originating from Juntendo University, has raised 220 million yen in funding through a third-party allotment of shares in a seed round and a subsequent Series A, with Sumitomo Corporation, Nippon Chemiphar Co., Ltd., SEED Co., Ltd., and JINS HOLDINGS Inc. as the primary underwriters.

Based on the funds raised this time, we will further accelerate the development of products and platforms to translate the medical research results we have built up to now into social implementation. Furthermore, we will work with our investment partner companies and other healthcare-related companies to construct exit strategies for smooth market introduction, aiming to provide solutions to more patients and medical professionals, faster.